http://groups.google.com/group/subhadra-nambudiri-foundation/browse_thread/thread/b015aa32f38c799/a2be86def30118a1?q=stroke+research#a2be86def30118a1
Feb 9 2010, 12:28 am
Feb 9 2010, 12:28 am
Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today
announced that the results of a pre-clinical study in an animal model
of ischemic stroke demonstrated that its PLacental eXpanded (PLX) cell
therapy may be an effective treatment for this disorder. Results will
be published in the journal Brain Research (Brain Research, Feb. 22,
Vol. 1315) under the title "Transplantation of placenta-derived
mesenchymal stromal cells upon experimental stroke in rats." The study
was conducted in collaboration with the Fraunhofer Institute for
Immunology and Cell Therapy (IZI) in Leipzig, Germany.
The study indicates that in animals treated with PLX cells, there were
significant differences to the control groups in the following
parameters:
- Improvement in sensory and motor deficits
- Reduction in the development of the stroke lesion
- Increase in the production of glial nerve tissue
These effects occurred even though the PLX cells were administered
eight and 24 hours after the inducement of the stroke. This suggests
that the use of PLX cells in ischemic stroke may allow patients a
longer window of time for successful treatment after the onset of the
insult. Optimal current therapy dictates that patients must be treated
within four and a half hours after the onset of ischemic stroke. PLX
cells may increase this window from four and a half hours up to eight
hours.
The authors of the study hypothesized that systematically transplanted
PLX cells migrated toward the ischemic part of the brain and secreted
soluble factors with considerable effects on cell death processes
(apoptosis), neuron growth (neurogenesis), blood vessel growth
(angiogenesis) and neuronal remodeling.
"The study's positive results suggest that PLX cells may increase the
time interval for successful treatment in humans suffering from
ischemic stroke, but our knowledge concerning modes of action and
optimal treatment paradigms must be enlarged in further experiments
before considering clinical application," said Dr. Johannes Boltze,
head of the stroke research group at The Fraunhofer Institute for IZI
in Leipzig, Germany and senior author of the publication.
Zami Aberman, chairman and CEO of Pluristem, added, "This study is
further evidence that PLX cells may be effective in treating various
diseases including ischemic stroke."
Source : Pluristem Therapeutics Inc.
--------------------------------------------------------------
About-us:
The Subhadra Nambudiri Foundation (SNF) is a registered Public
Charitable Trust set up with the primary objective of creating
awareness in the society about brain stroke, the silent killer, and
diseases leading to it such as Diabetes and High Blood Pressure.
The Foundation was set up by Mr. K G Suresh, a Senior Delhi-based
Journalist and Ms. Sunita Govind, an independent Media Consultant, in
fond memory of their mother who died on December 18, 2000, following
a massive brain stroke at the young age of 56.
On the occassion of her 65th birth anniversary on June 14, 2009, we
have launched a daily brain stroke news bulletin, comprising news
items and development pertaining to the 'silent killer' including
research, statistics, initiatives by government, NGOs, pharma
companies etc.
Given your keen interest in Continuing Medical Education (CME), we
hope you find this complimentary bulletin useful and informative.
However, in case you are not interested, please send us a return mail
mentioning simply "NOT INTERSTED".
We look forward to your valuable inputs and suggestions.
No comments:
Post a Comment